Skip to main content
SpringerLink
Log in

First-Line Treatment and the New Paradigm of Histology-Based Treatment

  • Chapter
  • First Online:
Book cover Management of Lung Cancer in Older People

  • 1082 Accesses

Abstract

Today, no data are available concerning the histological NSCLC subtypes and treatment in elderly population in which the relationship between histology and therapy can be extrapolated from that of general population. Thus, pemetrexed and bevacizumab can be used in non-squamous histology due to a better efficacy or for safety concerns, respectively. Squamous cell carcinoma could benefit from third-generation-based treatment due to the lack of biological agents resulting active in this histology. The diagnosis of NSCLC NOS is still frequent, but the new immunohistochemical techniques, better defining the histotype, are reducing the incidence of this histology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gabrielson E. Worldwide trends in lung cancer pathology. Respirology. 2006;11:533–8.

    Article  PubMed  Google Scholar 

  2. Strauss GM, Jemal A, McKenna MB, et al. The epidemic of smoking-related adenocarcinoma of the lung: the role of the tobacco industry and filtered and low-tar cigarettes. J Thorac Oncol. 2007;2 Suppl 4:S305 (abstr. PRS-01).

    Article  Google Scholar 

  3. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist. 2009;14:253–63.

    Article  PubMed  CAS  Google Scholar 

  4. Hirsch FR, Spreafico A, Novello S, et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol. 2008;3:1468–81.

    Article  PubMed  Google Scholar 

  5. Georgoulias V, Papadakis E, Alexopoulos A, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet. 2001;357:1478–84.

    Article  PubMed  CAS  Google Scholar 

  6. Scagliotti GV, de Marinis F, Rinaldi M, et al. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol. 2009;4:1568–71.

    PubMed  Google Scholar 

  7. Tan EH, Rolski J, Grodzki T, et al. Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol. 2009;20:1249–56.

    Article  PubMed  CAS  Google Scholar 

  8. Azzoli CG, Baker Jr S, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27:6251–66.

    Article  PubMed  CAS  Google Scholar 

  9. Felip E, Gridelli C, Baas P, et al. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol. 2011;22:1507–19.

    Article  PubMed  CAS  Google Scholar 

  10. de Marinis F, Rossi A, Di Maio M, et al. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer. 2011;73:1–10.

    Article  PubMed  Google Scholar 

  11. Langer CJ, Vangel M, Schiller J, et al. Age-specific subanalysis of ECOG 1594: fit elderly patients (70–80 yrs) with NSCLC do as well as younger pts (<70). Proc Am Soc Clin Oncol. 2003;22:639 (abstr. 2571).

    Google Scholar 

  12. Hensing TA, Peterman AH, Schell MJ, et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003;98:779–88.

    Article  PubMed  CAS  Google Scholar 

  13. Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer. 2005;104:2766–74.

    Article  PubMed  CAS  Google Scholar 

  14. Ramalingam S, Perry MC, La Rocca RV, et al. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer. 2008;113:542–6.

    Article  PubMed  CAS  Google Scholar 

  15. Blanchard EM, Moon J, Hesketh PJ, et al. Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509. J Thorac Oncol. 2011;6:115–20.

    Article  PubMed  Google Scholar 

  16. Perrone F, Gallo C, Gridelli C. Re: cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002;94:1029–31.

    Article  PubMed  Google Scholar 

  17. Gridelli C, Brodowicz T, Langer CJ, et al. Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small cell lung cancer. Clin Lung Cancer. 2012;13(5):340–6.

    Article  PubMed  CAS  Google Scholar 

  18. Gridelli C, Thomas M, Prabhash K, et al. Pemetrexed (pem) maintenance therapy in elderly patients (pts) with good performance status (PS) – analysis of PARAMOUNT phase III study of pem versus placebo in advanced nonsquamous non-small cell lung cancer (NSCLC). Eur J Cancer. 2011;47 Suppl 1:S613 (abstr. 9072).

    Article  Google Scholar 

  19. Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008;26:60–5.

    Article  PubMed  CAS  Google Scholar 

  20. Leighl N, Zatloukal P, Mezger J, et al. Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol. 2010;5:1970–6.

    Article  PubMed  Google Scholar 

  21. Griesinger F, Pavlakis N, Garrido P, et al. MO19390 (SAiL): safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). J Thorac Oncol. 2009;4 suppl 1:S359 (abstr. C2.6).

    Google Scholar 

  22. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non small cell lung cancer. J Natl Cancer Inst. 1999;91:66–72.

    Article  Google Scholar 

  23. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJOG 9904). J Clin Oncol. 2006;24:3657–63.

    Article  PubMed  CAS  Google Scholar 

  24. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2000;18:2529–36.

    PubMed  CAS  Google Scholar 

  25. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362–72.

    Article  PubMed  CAS  Google Scholar 

  26. Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378:1079–88.

    Article  PubMed  CAS  Google Scholar 

  27. Abe T, Yokoyama A, Takeda K, et al. Randomized phase III trial comparing weekly docetaxel (D)-cisplatin (P) combination with triweekly D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): an intergroup trial of JCOG0803/WJOG4307L. J Clin Oncol. 2011;29:478s (abstr. 7509).

    Google Scholar 

  28. Biesma B, Wymenga ANM, Vincent A, et al. Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. Ann Oncol. 2011;22:1520–7.

    Article  PubMed  CAS  Google Scholar 

  29. Gridelli C, Maione P, Rossi A. Therapy for elderly patients with advanced non-small cell lung cancer. In: 47th annual meeting of American Society of Clinical Oncology Educational Book. Alexandria, VA: American Society of Clinical Oncology; 2011. p. 300–4.

    Google Scholar 

  30. Gridelli C, Maione P, Illiano A, et al. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol. 2007;25:4663–9.

    Article  PubMed  CAS  Google Scholar 

  31. Rossi A, Galetta D, Gridelli C. Biological prognostic and predictive factors in lung cancer. Oncology. 2009;77 Suppl 1:90–6.

    Article  PubMed  Google Scholar 

  32. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signalling pathway in lung cancers. Int J Cancer. 2006;118:257–62.

    Article  PubMed  CAS  Google Scholar 

  33. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–8.

    Article  PubMed  CAS  Google Scholar 

  34. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8.

    Article  PubMed  CAS  Google Scholar 

  35. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12:735–42.

    Article  PubMed  CAS  Google Scholar 

  36. Rosell R, Gervais R, Vergnenegre A, et al. Erlotinib vs chemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) activating mutations: Interim results of the European Tarceva vs Chemotherapy (EURTAC) phase III randomized trial. J Clin Oncol. 2011;29(15S):476s (abstr. 7503).

    Google Scholar 

  37. Mineshi Y, Maemondo M, Okinaga S, et al. First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: multicenter phase II trial (NEJ 003 study). J Clin Oncol. 2010;28(18S):553s (abstr. 7561).

    Google Scholar 

  38. Crinò L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol. 2008;26:4253–60.

    Article  PubMed  Google Scholar 

  39. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naïve patients ≥70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007;25:760–6.

    Article  PubMed  CAS  Google Scholar 

  40. Spigel DR, Hainsworth JD, Shipley DL, et al. A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer. J Thorac Oncol. 2012;7(1):196–202.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology/Hematology, S.G. Moscati Hospital, Avellino, Italy

    Cesare Gridelli MD

  2. Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy

    Antonio Rossi MD & Paolo Maione MD

Authors
  1. Cesare Gridelli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio Rossi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paolo Maione MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cesare Gridelli MD .

Editor information

Editors and Affiliations

  1. , Department of Oncology/Hematology, S.G. Moscati Hospital, Contrada Amoretta, Avellino, 83100, Italy

    Cesare Gridelli

  2. St Helens Teaching Hospital, University of Liverpool, Marshalls Cross Road, St Helens, WA9 3DA, United Kingdom

    Riccardo A Audisio

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Gridelli, C., Rossi, A., Maione, P. (2013). First-Line Treatment and the New Paradigm of Histology-Based Treatment. In: Gridelli, C., Audisio, R. (eds) Management of Lung Cancer in Older People. Springer, London. https://doi.org/10.1007/978-0-85729-793-8_14

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-793-8_14

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-792-1

  • Online ISBN: 978-0-85729-793-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation